AK MEDICAL HOLDINGS LIMITED
愛康醫療控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1789)

VOLUNTARY ANNOUNCEMENT
CERTIFICATION BY NMPA

This announcement is made by AK Medical Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to keep its shareholders and potential investors informed of the latest business development of the Company.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the Company obtained the certification for Acetabular Component of Hip Prosthesis Class III medical devices approved by the National Medical Products Administration ("**NMPA**") of the People's Republic of China (the "**PRC**") on 30 November 2023.

3D-printed titanium alloy orthopedic implants are now widely used in clinical applications and have achieved good clinical application results. However, since titanium alloy is a biologically inert material, it is difficult to form a bioactive bond with the bone tissue after implantation into human bodies. As such, the first generation of 3D-printed titanium alloy orthopedic implants still require further improvement in their biological functions.

Since obtaining the first certification for 3D-printed orthopedic implants in the PRC in 2015, the Group has dedicated itself to the development of 3D-printed orthopedic technology and product upgrades, and established a technology platform for surface modification for 3D-printed porous titanium alloy implants. Accordingly, the Group has developed 3DACT Bio® Technology and having such intellectual property rights, introduced bioactive substances such as Ca/P on the surface of porous titanium alloy implants, and developed 3D-printed titanium alloy joint and spine and other products with bioactive functions. The approval of the certification for the Second-generation Acetabular Component of Hip Prosthesis with bioactive function realises the development breakthrough of 3D-printed porous titanium alloy implants from bioinertness to bioactive functionality, and upgrades from the First-generation 3D-printed porous titanium alloy implants to a product that enables the bioactive combination with the bone tissue. The Second-generation of 3D-printed orthopaedic implants with bioactive functions based on 3DACT Bio® technology is a new breakthrough in the Group's continuous research and development of 3D-printed orthopaedic implant technology, realising the upgrade of 3D-printed orthopaedic implants.

By Order of the Board
AK Medical Holdings Limited
Li Zhijiang
Chairman

Hong Kong, 7 December 2023

As at the date of this announcement, the Board comprises Mr. Li Zhijiang, Ms. Zhang Bin, Mr. Zhang Chaoyang and Ms. Zhao Xiaohong as executive Directors, Dr. Wang David Guowei as non-executive Director, and Mr. Kong Chi Mo, Dr. Li Shu Wing David and Mr. Eric Wang as independent non-executive Directors.